APA

Alumkal J. J., Chowdhury S., Loriot Y., Sternberg C. N., de Bono J. S., Tombal B., Carles J., Flaig T. W., Dorff T. B., Phung D., Forer D., Noonberg S. B., Mansbach H., Beer T. M. & Higano C. S. (20180521). Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. : Clinical genitourinary cancer.

Chicago

Alumkal Joshi J, Chowdhury Simon, Loriot Yohann, Sternberg Cora N, de Bono Johann S, Tombal Bertrand, Carles Joan, Flaig Thomas W, Dorff Tanya B, Phung De, Forer David, Noonberg Sarah B, Mansbach Hank, Beer Tomasz M and Higano Celestia S. 20180521. Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. : Clinical genitourinary cancer.

Harvard

Alumkal J. J., Chowdhury S., Loriot Y., Sternberg C. N., de Bono J. S., Tombal B., Carles J., Flaig T. W., Dorff T. B., Phung D., Forer D., Noonberg S. B., Mansbach H., Beer T. M. and Higano C. S. (20180521). Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. : Clinical genitourinary cancer.

MLA

Alumkal Joshi J, Chowdhury Simon, Loriot Yohann, Sternberg Cora N, de Bono Johann S, Tombal Bertrand, Carles Joan, Flaig Thomas W, Dorff Tanya B, Phung De, Forer David, Noonberg Sarah B, Mansbach Hank, Beer Tomasz M and Higano Celestia S. Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. : Clinical genitourinary cancer. 20180521.